Publications

Efficacy and Safety of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) in Adolescent and Adult Patients With Hereditary Angioedema: Phase 3 Trial Design

Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA , Audhya PK, Smith MD, Yea CM, Lumry WR, Riedl MA, Maurer M

EAACI 2022

Novel Oral Small Molecule FXIIa Inhibitor Blocks Contact System Activation In Vivo

Clermont A

EAACI 2022

Population Pharmacokinetic Analysis of Sebetralstat (KVD900) in Healthy Adult Volunteers and Patients With Hereditary Angioedema Predicts Similar Exposure in Adolescent Patients

Smith MD, Rodgers T, Sharman J, Mutch P, Tachdjian R, Savic S,  Farrell C

EAACI 2022

Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary Angioedema

Aygören-Pürsün E, Zanichelli A, Cohn DM, Audhya PK, Williams P, Yea CM, Smith MD

EAACI 2022

Oral factor XIIa inhibition blocks angiotensin converting enzyme inhibitor induced angioedema in mouse

Clermont AC, Murugesan N, Feener EP

KININ 2022

Oral FXIIa inhibitor KV998086 suppresses FXII zymogen mediated kallikrein kinin system activation

Murugesan N, Lee DK, Duckworth EJ, Smith SA, Clermont AC, Hampton SL, Feener EP

KININ 2022

Oral sebetralstat (KVD900) provides rapid inhibition of the kallikrein kinin system in patients with hereditary angioedema

Duckworth EJ, Lee DK, Murugesan N, Rushbrooke L, Hampton SL, Smith M, Yea C, Audhya P, Feener EP

KININ 2022

KONFIDENT Phase 3 Trial Design for Sebetralstat (KVD900), a Novel Investigational Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angloedema Attacks

Lumry WR, Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA, Audhya PK, Smith MD, Yea CM, Riedl MA, Maurer M

EAC 2022

Agreement Between Improvements in Patient Global Impression of Change and Other Measures of Improvement and Attack Resolution Observed in a Phase 2 Trial With Sebetralstat (KVD900) in Patients With Hereditary Angioedema

Audhya P, Smith MD, Williams P, Yea CM, Cohn DM

EAC 2022

Oral Sebetralstat (KVD900) Provides Rapid Inhibition of Plasma Kallikrein and Fast Improvement in Attack Symptoms in Patients With Hereditary Angioedema

Smith MD, Duckworth EJ, Hampton SL, Yea CM, Audhya P, Feener EP

 EAC 2022

Agreement of Patient Global Impression of Change With Attack Resolution or Use of Rescue Medication in Patients With Hereditary Angioedema
Audhya P, Williams P, Yea C, Cohn D

AAAAI 2022

Rapid Plasma Kallikrein Inhibition Following Oral KVD900 Is Associated With Early Symptom Relief in Patients With Hereditary Angioedema
Duckworth EJ, Feener EP, Yea CM, Audhya P, Hampton SL, Smith MD

AAAAI 2022

KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results
Maetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM

PMID: 35086692

On-demand Oral Treatment With KVD900 for HAE Attacks Achieves Rapid Exposure and Improves Patient Outcomes
Bernstein JA, Huamin LH, Yea CM, Maetzel A, Audhya P, Williams P, Banerji A, Riedl MA

ACAAI 2021

Relationship Between PGI-C Scale and Other PROs in KVD900 Trial in Hereditary Angioedema
Audhya P, Williams P, Yea CM

ACAAI 2021

A single on-demand treatment with orally administered KVD900 significantly slows progression and accelerates resolution of attacks in patients with hereditary angioedema (HAE): Results of a phase 2, placebo-controlled, double-blind cross-over trial
Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Cancian M, Hakl R, Kinaciyan T, Magerl M, Martinez-Saguer I, Stobiecki M, Grivcheva-Panovska V, Kiani-Alikhan S, Krcmova I, Bernstein J, Manning M, Stroud C, Hanzlikova J, Li HH, Longhurst HJ, Melamed IR, Young P, Feener E, Iverson M, Maetzel A, Morten RM, Smith MD, Watissée MI, Williams P, Yea CM, Maurer M, Banerji A, and Riedl MA

EAACI 2021

A single on-demand treatment with orally administered KVD900 significantly slows progression and accelerates resolution of attacks in patients with hereditary angioedema (HAE): Results of a phase 2, placebo-controlled, double-blind cross-over trial
Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Cancian M, Hakl R, Kinaciyan T, Magerl M, Martinez-Saguer I, Stobiecki M, Grivcheva-Panovska V, Kiani-Alikhan S, Krcmova I, Bernstein J, Manning M, Stroud C, Hanzlikova J, Li HH, Longhurst HJ, Melamed IR, Young P, Feener E, Iverson M, Maetzel A, Morten RM, Smith MD, Watissée MI, Williams P, Yea CM, Maurer M, Banerji A, and Riedl MA

EAACI 2021

Prevalence of hereditary angioedema with normal C1-inhibitor (nC1-HAE) in the United States: Results from a nationwide survey of HAE-treating physicians
Riedl MA, Danese M, Danese S, Ulloa J, and Maetzel A

EAACI 2021

Current management of hereditary angioedema with normal C1-inhibitor (nC1-HAE) in the United States: Results from a nationwide survey of HAE-treating physicians
Riedl MA, Danese M, Danese S, Ulloa J, and Maetzel A

EAACI 2021

Oral plasma kallikrein inhibitor KV998052 improves arterial blood oxygenation in a murine model of acute respiratory distress syndrome (ARDS)
Murugesan N, Clermont AC, and Feener EP

EAACI 2021

Selective Factor XIIa inhibitor KV998083 protects mice against captopril induced vascular leakage and cleavage of high molecular weight kininogen
Clermont AC, Murugesan N, Edwards HJ, Whitney SA, Pethen SJ, Duckworth EJ, Hampton SL, Feener EP

EAACI 2021

Fast improvement of hereditary angioedema (HAE) attacks with the oral on-demand plasma kallikrein inhibitor KVD900: an analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom severity during a double-blind, randomized phase 2 cross-over trial in patients with HAE type I and II
Zanichelli, Andrea

C1-INHIBITOR WORKSHOP 2021

One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study
Sun JK, Maturi RK, Boyer DS, Wells JA, Gonzalez VH, Tansley R, Hernandez H, Maetzel A, Feener EP, Aiello LP.

OPHTHALMOLOGY RETINA

Rapid and nearly complete suppression of plasma kallikrein activity with the oral inhibitor KVD900: results of a phase 1 study evaluating KVD900's potential as a treatment for acute attacks of HAE
Maetzel A, Smith MD, Morten RM, Hampton SL, De Donatis GM, Murugesan NI, Rushbrooke LJ, Li L, Duckworth EJ, Feener EP, Yea C.

EAACI 2019

High plasma exposures of KVD900 achieved in First in Human study markedly inhibit plasma prekallikrein activation; early blockade of plasma kallikrein (PKa) may halt attacks in Hereditary Angioedema (HAE) by reducing contact system activation.
Duckworth EJ, Hampton SL, Li L, Murugesan N, Rushbrooke L, Smith M, Morten R, Maetzel A, Yea C, and Feener EP.

C1-INHIBITOR WORKSHOP 2019

Novel oral plasma kallikrein (PKa) inhibitors KV998052 and KV998054 ameliorate VEGF-induced retinal thickening in a murine model of retinal edema.
Murugesan N, Clermont AC, Pethen SJ, Li L, Duckworth EJ, Hampton SL, and Feener EP.

ARVO 2019

KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic results from a Phase 1 Single Ascending Dose Study.
Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Duckworth E, Smith MD, Morten RM, Maetzel A, Yea CM and Feener EP.
AAAAI 2019

Efficacy of plasma kallikrein inhibitors in plasma is dependent on the rate of formation of the enzyme-inhibitor complex.
De Donatis GM, Murugesan N, Duckworth E, Robson PA, Li L, Rushbrooke LJ, Feener EP and Hampton SL.
KININ 2018

KVD900 protects high molecular weight kininogen (HK) from ex vivo plasma kallikrein-mediated cleavage in plasma from patients with hereditary angioedema (HAE): Results from a semi-automated capillary-based immunoassay.
Feener EP, Murugesan N, Robson PA, Li L, Rushbrooke LJ, Thoonen R, De Donatis GM, Riedl M, Zuraw B, and Hampton SL.
EAACI 2018

A novel oral plasma kallikrein (PKal) inhibitor KV123833 blocks VEGF-mediated retinal vascular hyperpermeability in a murine model of retinal edema (#3464).
Murugesan N, Clermont AC, Rushbrooke LJ, Robson PA, Thoonen R, Pethen SJ, Hampton SL, and Feener EP. 
ARVO 2018

Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
Simao F, Ustunkaya T, Clermont AC, and Feener EP. 
Blood. 2017.
PMID:28130211

Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening.
Clermont A, Murugesan N, Zhou Q, Kita T, Robson PA, Rushbrooke LJ, Evans DM, Aiello LP, and Feener EP.
Invest Ophthalmol Vis Sci. 2016; 57:2390-9.
PMID:27138737

Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema.
Kita T, Clermont AC, Murugesan N, Zhou Q, Fujisawa K, Ishibashi T, Aiello LP, Feener EP.
Diabetes. 2015; 64:3588-99.
PMID:25979073

Intraocular hemorrhage causes retinal vascular dysfunction via plasma kallikrein.
Liu J, Clermont AC, Gao BB, Feener EP.
Invest Ophthalmol Vis Sci. 2013;54:1086-1094.
PMID:23299478

Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats.
Clermont A, Chilcote TJ, Kita T, Liu J, Riva P, Sinha S and Feener EP.
Diabetes. 2011;60(5):1590-8.
PMID:21444925

Hyperglycemia induced cerebral hematoma expansion is mediated by plasma kallikrein.
Liu J, Gao B-B, Clermont AC, Blair P, Chilcote TJ, Sinha S, Flaumenhaft R and Feener EP.
Nature Medicine. 2011;17:206-10.
PMID:21258336

Plasma kallikrein and diabetic macular edema.
Feener EP.
Curr. Diab. Rep. 2010 Aug; 10(4):270-5.
PMID:20535647

Plasma kallikrein mediates angiotensin AT1 receptor stimulated retinal vascular permeability.
Phipps JA, Clermont AC, Sinha S, Chilcote TJ, Bursell S-E, and Feener EP.
Hypertension 2009; 53:175-81.
PMID:19124682

The kallikrein-kinin system in diabetic retinopathy: Lessons for the kidney.
Phipps JA and Feener EP.
Kidney Int., 2008;73(10):1114-9.
PMID:18272958

Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.
Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, Aiello LP and Feener EP.
Nature Medicine. 2007;13:181-8.
PMID:17259996